US equities |
MU $1,040.60 ▼-4.36% NVDA $230.25 ▼-3.04% SNDK $1,610.99 ▼-4.81% AMD $616.66 ▼-4.52% INTC $106.33 ▼-6.00% SPCX $162.22 ▼-3.21% META $719.37 ▼-0.27% MSFT $521.60 ▼-1.54%
FinancialContent

Articles published by TherapeuticsMD, Inc.

News headline image
TherapeuticsMD Announces Second Quarter 2026 Financial Results
From TherapeuticsMD, Inc.
Via Business Wire
Tickers TXMD
News headline image
TherapeuticsMD Announces First Quarter 2026 Financial Results
From TherapeuticsMD, Inc.
Via Business Wire
Tickers TXMD
News headline image
TherapeuticsMD Announces Full Year 2025 Financial Results
From TherapeuticsMD, Inc.
Via Business Wire
Tickers TXMD
News headline image
TherapeuticsMD Announces Third Quarter 2025 Financial Results
From TherapeuticsMD, Inc.
Via Business Wire
Tickers TXMD
News headline image
TherapeuticsMD Announces Second Quarter 2025 Financial Results
From TherapeuticsMD, Inc.
Via Business Wire
Tickers TXMD
News headline image
TherapeuticsMD Announces First Quarter 2025 Financial Results
From TherapeuticsMD, Inc.
Via Business Wire
Tickers TXMD
News headline image
TherapeuticsMD Announces Full Year 2024 Financial Results
From TherapeuticsMD, Inc.
Via Business Wire
Tickers TXMD
News headline image
TherapeuticsMD Announces Third Quarter 2024 Financial Results
From TherapeuticsMD, Inc.
Via Business Wire
Tickers TXMD
News headline image
TherapeuticsMD Announces Second Quarter 2024 Financial Results
From TherapeuticsMD, Inc.
Via Business Wire
Tickers TXMD
News headline image
TherapeuticsMD Announces First Quarter 2024 Financial Results
From TherapeuticsMD, Inc.
Via Business Wire
Tickers TXMD
News headline image
TherapeuticsMD Announces Full Year 2023 Financial Results
From TherapeuticsMD, Inc.
Via Business Wire
Tickers TXMD
News headline image
TherapeuticsMD Announces Third Quarter 2023 Financial Results
From TherapeuticsMD, Inc.
Via Business Wire
Tickers TXMD
News headline image
TherapeuticsMD Announces Second Quarter 2023 Financial Results
From TherapeuticsMD, Inc.
Via Business Wire
Tickers TXMD
News headline image
TherapeuticsMD Announces First Quarter 2023 Financial Results
From TherapeuticsMD, Inc.
Via Business Wire
Tickers TXMD
News headline image
TherapeuticsMD Announces Full Year 2022 Financial Results and Provides Update on Business Model Transition
From TherapeuticsMD, Inc.
Via Business Wire
Tickers TXMD
News headline image
TherapeuticsMD Completes Transaction to License Its Products to Mayne Pharma
From TherapeuticsMD, Inc.
Via Business Wire
Tickers TXMD
News headline image
TherapeuticsMD Announces Definitive Agreements to License its Products to Mayne Pharma
From TherapeuticsMD, Inc.
Via Business Wire
Tickers TXMD
News headline image
TherapeuticsMD Announces Third Quarter 2022 Financial Results
From TherapeuticsMD, Inc.
Via Business Wire
Tickers TXMD
News headline image
TherapeuticsMD Announces Additional $7 Million Private Placement
From TherapeuticsMD, Inc.
Via Business Wire
Tickers TXMD
News headline image
TherapeuticsMD Announces $7 Million Private Placement
From TherapeuticsMD, Inc.
Via Business Wire
Tickers TXMD
News headline image
TherapeuticsMD Appoints Dr. Brian Bernick and Mr. Mark Glickman as Interim Co-Chief Executive Officers
From TherapeuticsMD, Inc.
Via Business Wire
Tickers TXMD
News headline image
TherapeuticsMD Announces Second Quarter 2022 Financial Results
From TherapeuticsMD, Inc.
Via Business Wire
Tickers TXMD
News headline image
TherapeuticsMD to Report Second Quarter 2022 Financial Results on August 15, 2022
From TherapeuticsMD, Inc.
Via Business Wire
Tickers TXMD
News headline image
TherapeuticsMD Secures $15 Million Equity Investment from Rubric Capital
From TherapeuticsMD, Inc.
Via Business Wire
Tickers TXMD
News headline image
TherapeuticsMD Announces Expiration of Tender Offer
From TherapeuticsMD, Inc.
Via Business Wire
Tickers TXMD
News headline image
TherapeuticsMD and EW Healthcare Partners Announce Definitive Agreement for EW Healthcare Partners to acquire TherapeuticsMD
From TherapeuticsMD, Inc.
Via Business Wire
Tickers TXMD
News headline image
TherapeuticsMD Receives U.S. Food and Drug Administration (FDA) Approval for Supplemental New Drug Application (sNDA) for ANNOVERA®
From TherapeuticsMD, Inc.
Via Business Wire
Tickers TXMD
News headline image
TherapeuticsMD Announces First Quarter 2022 Financial Results
From TherapeuticsMD, Inc.
Via Business Wire
Tickers TXMD
News headline image
TherapeuticsMD to Report First Quarter 2022 Financial Results on May 16, 2022
From TherapeuticsMD, Inc.
Via Business Wire
Tickers TXMD
News headline image
TherapeuticsMD Completes the Divestiture of vitaCare Prescription Services to GoodRx in a Cash Transaction Valued at $150 Million
From TherapeuticsMD, Inc.
Via Business Wire
Tickers TXMD